Meta-Targeting SIGNED
Macro-Nanomedicine to Treat Metastatic Cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Meta-Targeting project word cloud
Explore the words cloud of the Meta-Targeting project. It provides you a very rough idea of what is the project "Meta-Targeting" about.
Project "Meta-Targeting" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITAETSKLINIKUM AACHEN
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 1˙979˙375 € |
| EC max contribution | 1˙979˙375 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2019-COG |
| Funding Scheme | ERC-COG |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-04-01 to 2025-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITAETSKLINIKUM AACHEN | DE (AACHEN) | coordinator | 1˙979˙375.00 |
Map
Project objective
Metastatic cancer is a complex and highly heterogenous disease, which is very difficult to treat. The aim of the Meta-Targeting project is to establish a holistic, rational and realistic nanomedicine-based approach to improve the treatment of metastatic breast cancer. Concrete objectives are: (1) the development of polymeric micelles which can be efficiently and stably co-loaded with three different drugs and with an imaging agent; (2) the use of physical and pharmacological means to modulate the vasculature and microenvironment in tumors and metastases; (3) the identification of imaging- and biopsy-based biomarkers for patient selection; (4) the incorporation of drugs to overcome cellular and microenvironmental multidrug resistance; and (5) the implementation of multifunctional micelles to enhance the efficacy of immunotherapy. It is envisaged that micelles loaded with in-house developed doxorubicin prodrugs are able to induce immunogenic cell death in tumors and metastases without causing systemic immunodepression, that co-loading with the angiotensin receptor inhibitor losartan helps to prime tumors and metastases for improved delivery (of micelles, immunomodulatory antibodies and T cells), and that co-loading with the P-glycoprotein inhibitor tariquidar assists in inducing immunogenic cell death, while avoiding typical anti-Pgp side effects, such as neurotoxicity. Physical priming with ultrasound and microbubbles will promote the delivery of micelles, antibodies and T cells to and into primary tumors. Imaging- and biopsy-based biomarkers are needed to allow for patient stratification, which is critically important to improve the clinical translation of cancer nanomedicines. The outcomes of the different project lines in Meta-Targeting will - alone and especially together - be truly transformative: they will contribute to scientific and clinical progress in nanomedicine, in tumor-targeted drug delivery, in immunotherapy, and in the treatment of metastatic cancer.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "META-TARGETING" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "META-TARGETING" are provided by the European Opendata Portal: CORDIS opendata.